Publications by authors named "Sivan Harnik"

Article Synopsis
  • Small molecule drugs are increasingly utilized for treating inflammatory bowel diseases (IBD), but their pharmacokinetics involve complex interactions influenced by other medications, patient characteristics, and food intake.
  • This review offers a practical guide for IBD physicians, outlining key metabolizing enzymes and FDA guidelines on drug interaction risks, followed by an in-depth look at five recently approved small molecules (Tofacitinib, Upadacitinib, Filgotinib, Ozanimod, and Etrasimod) and their specific interactions.
  • It emphasizes the necessity for healthcare professionals to assess potential drug-drug interactions before prescribing these small molecule drugs, highlighting challenges in understanding the impact of multiple medications on patient care.
View Article and Find Full Text PDF
Article Synopsis
  • A study investigated the effectiveness of adalimumab, an anti-TNFα monoclonal antibody, in ulcerative colitis (UC) patients, revealing that fewer UC patients continued treatment compared to those with Crohn's disease (CD).
  • In a cohort of 50 UC patients, only 22% maintained treatment through the follow-up period, while 51% of 98 CD patients did.
  • The loss of response to treatment was notably higher in UC patients, with 34% developing antibodies against adalimumab, although immunogenicity rates were similar between both patient groups.
View Article and Find Full Text PDF

Background & Aims: Noninvasive modalities for assessing active endoscopic and histologic inflammation in Crohn's disease and ulcerative colitis patients are critically needed. Fecal wash host shed-cell transcriptomics has been shown to be a robust classifier of endoscopic and histologic inflammation in inflammatory bowel disease patients with distal colitis. Whether such fecal washes can inform on inflammatory processes occurring in more proximal intestinal segments is currently unknown.

View Article and Find Full Text PDF